The main groups of Mabs in SCC therapy are Mabs targeting EGFR, HER2, HGF, and VEGF, alongside checkpoint inhibitors (including Mabs to PD‐1, CTLA4, and NKG2A) and tumor targeting Mabs. Here, KLRC1 is linked to neoplasm.